Document Detail

Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients.
MedLine Citation:
PMID:  22864282     Owner:  NLM     Status:  MEDLINE    
Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis. We investigated the safety and efficacy of levofloxacin compared with ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. This was a multicenter, open-label, randomized controlled non-inferiority trial. Four hundred and seventy-one patients with clinical symptoms/signs were enrolled into the study, and 408 patients were microbiologically confirmed chronic bacterial prostatitis, who were randomized to either oral levofloxacin (500 mg q.d.) or ciprofloxacin (500 mg b.i.d.) for 4 weeks. Bacterial clearance rate, clinical symptoms/signs, adverse reactions and disease recurrence were assessed. The clinical symptoms and signs (including dysuria, perineal discomfort or pain) and bacteria cultures in 209 patients treated with levofloxacin and 199 patients treated with ciprofloxacin were similar. The most common bacteria were Escherichia coli and Staphylococcus aureus. One to four weeks after the end of 4 weeks treatment, the bacterial clearance rate (86.06% vs. 60.03%; P<0.05) and the clinical efficacy (including clinical cure and clinical improvement(93.30% vs. 71.86%; P<0.05)) were significantly higher in the levofloxacin-treated group than in the ciprofloxacin-treated group. The microbiological recurrence rate was significantly lower in the levofloxacin-treated group than in the ciprofloxacin-treated group (4.00% vs. 19.25%; P<0.05). Rates of adverse events and treatment-related adverse events were slightly lower in the levofloxacin-treated group than in ciprofloxacin-treated group. Levofloxacin showed some advantages over ciprofloxacin in terms of clinical efficacy and disease recurrence, with a low rate of adverse events, for the treatment of chronic bacterial prostatitis in Chinese patients.
Zhi-Chao Zhang; Feng-Shuo Jin; Dong-Ming Liu; Zhou-Jun Shen; Ying-Hao Sun; Ying-Lu Guo
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-08-06
Journal Detail:
Title:  Asian journal of andrology     Volume:  14     ISSN:  1745-7262     ISO Abbreviation:  Asian J. Androl.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-07     Completed Date:  2013-04-22     Revised Date:  2013-09-17    
Medline Journal Info:
Nlm Unique ID:  100942132     Medline TA:  Asian J Androl     Country:  China    
Other Details:
Languages:  eng     Pagination:  870-4     Citation Subset:  IM    
Andrology Center, Peking University First Hospital, Institute of Urology, Peking University, Beijing 100034, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / adverse effects
Asian Continental Ancestry Group
Ciprofloxacin / adverse effects*,  therapeutic use
Escherichia coli Infections / drug therapy
Middle Aged
Ofloxacin / adverse effects*,  therapeutic use
Prostatitis / drug therapy*,  microbiology
Staphylococcal Infections / drug therapy
Staphylococcus epidermidis / drug effects
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 82419-36-1/Ofloxacin; 85721-33-1/Ciprofloxacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of surgical procedures on prostate tumor gene expression profiles.
Next Document:  Oscillating bubbles: a versatile tool for lab on a chip applications.